ClinicalTrials.gg
CompletedNCT00606021Updated Dec 26, 2011Results posted

A Study Comparing of Two Different Chemotherapy Regimens, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

A Phase 2 interventional study of pemetrexed and Best Supportive Care in Non Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 5 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-12-26.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.

Enrollment
83rd of 223
106 · median 64
Started
2008
with 13 others
Phase 2
128 of 227
12 open now
Registered
65th of 227
by date
Lead sponsor
40 of 227
Eli Lilly and Company

Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 83rd largest by enrollment of the 223 interventional ones that give a count, is one of 14 that started in 2008, is one of 128 in phase 2, and was the 65th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a multicenter, open-label, randomized, two-arm Phase 2 study comparing pemetrexed plus best supportive care with best supportive care alone as maintenance therapy following first-line treatment with a pemetrexed-cisplatin combination in patients with advanced non-squamous non-small cell lung cancer.

A total of approximately 100 patients are planned to be enrolled, and following completion of four cycles of pemetrexed-cisplatin (Induction Phase) those patients in which disease progression has not occurred will be randomized in a 2:1 ratio to one of two treatment arms (Maintenance Phase): Arm A (pemetrexed plus best supportive care) or Arm B (best supportive care alone).

03

Conditions studied

  • Non Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. You must be at least 18 years old
  2. You must have been diagnosed with non-squamous non-small cell lung cancer (NSCLC)
  3. You must have had no prior systemic anticancer therapy for lung cancer
  4. You must live close enough to the study doctor to be able to visit regularly for follow up
  5. You must have signed form indicating your willingness to take part in this study
  6. Your laboratory and medical history and tests must meet study requirements

Exclusion criteria

Exclusion criteria:

  1. Treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry
  2. Prior radiotherapy and surgery should be completed at least 4 weeks prior to initiation of treatment
  3. Serious concomitant systemic disorder (e.g., active infection including , or unstable cardiovascular disease)
  4. Prior other than NSCLC, carcinoma in situ of the cervix, or nonmelanoma skin cancer unless treated at least 5 years previously with no subsequent evidence of recurrence
  5. Presence of (by physical exam) third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry
  6. Significant weight loss (greater than 10%), over the previous 6 weeks before study entry
  7. Concurrent administration of any other antitumor therapy
  8. Inability to interrupt aspirin or other non-steroidal anti-inflammatory agents for a 5-day period (8-day period for long-acting agents such as piroxicam)
  9. Inability or unwillingness to take folic acid, dexamethasone (or equivalent) or vitamin B12 supplementation
  10. Pregnancy or breast-feeding
  11. You are allergic to pemetrexed
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    A: Pemetrexed + Best Supportive Care

    Pemetrexed: 500 milligrams per square meter (mg/m²) , intravenous (IV), Day 1 of each 21-day cycle for 6 cycles Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.

    Drug: pemetrexed · Drug: Best Supportive Care

  • Active comparator
    B: Best Supportive Care

    Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.

    Drug: Best Supportive Care

Interventions

  • 500 mg/m², IV, Day 1 of each 21-day cycle for 6 cycles

    Also known as: Alimta, LY231514

  • DrugBest Supportive Care

    Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival During Maintenance Phase

    Progression free survival is defined as the time from randomization until the date of progression of disease (PD) or death from any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD is ≥20% increase in sum of longest diameter of target lesions. PD in maintenance phase uses the last lesion assessment prior to randomization as the baseline assessment.

    Time frame: Randomization to progression of disease (PD) or date of death from any cause up to 30.9 months

Secondary outcomes

  1. Progression Free Survival During Overall Period (Induction Phase [IP] + Maintenance Phase [MP])

    Progression-free survival in overall period is defined as the time from the date of first dose of study drug during IP until the date of PD or death from any cause. PD was determined using RECIST criteria. PD is ≥20% increase in sum of longest diameter of target lesions. PD in overall period uses the screening lesion assessment prior to the induction phase as the baseline assessment.

    Time frame: First dose of study drug during IP to PD or date of death from any cause up to 33.6 months

  2. Overall Survival During Maintenance Phase

    Overall survival in maintenance phase is defined as the time from randomization to death. Participants who were alive were censored at the last contact.

    Time frame: Randomization to PD or date of death from any cause up to 31.3 months

  3. Overall Survival During Overall Period (IP + MP)

    Overall survival in overall period is defined as the time from first dose of study drug during IP to death. Participants who were alive were censored at the last contact.

    Time frame: First dose of study drug during IP to PD or date of death from any cause up to 34.1 months

  4. Number of Participants With Adverse Events (AEs) During Overall Period

    The list of serious adverse events (SAEs) and other non-serious adverse events (AEs) are in Adverse Events Section.

    Time frame: First dose of study drug during IP through overall study completion (up to 34.3) months

  5. Tumor Response Rate and Disease Control Rate After Induction Phase (IP)

    Tumor response rate (%) is the number of responders (participants with best response of CR or PR) divided by the number of participants qualified for tumor response according to RECIST criteria multiplied by 100. Disease control rate is percentage of participants with a best response of stable disease \[SD\], PR, or CR. CR=disappearance of all target lesions; PR=30% decrease in sum of longest diameter of target lesions; PD is≥20% increase in sum of longest diameter of target lesions. SD= neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

    Time frame: Randomization to measured PD up to 31.4 months

07

Results

Posted Dec 26, 2011
Limitations and caveats
Due to a mistake in the randomization parameters form, the randomization was actually implemented in the ratio of 1:1 instead of the planned ratio of 2:1.

Participant flow

Induction Phase
Participant flow — Induction Phase
MilestonePemetrexed Plus Cisplatin (Induction Phase)Pemetrexed Plus Best Supportive Care (Maintenance Phase)Best Supportive Care (Maintenance Phase)
Started10600
Completed1900
Not completed8700
Withdrew: Death7300
Withdrew: Physician decision200
Withdrew: Withdrawal by subject200
Withdrew: Lost to follow-up1000
Maintenance Phase
Participant flow — Maintenance Phase
MilestonePemetrexed Plus Cisplatin (Induction Phase)Pemetrexed Plus Best Supportive Care (Maintenance Phase)Best Supportive Care (Maintenance Phase)
Started02827
Completed0510
Not completed02317
Withdrew: Death01715
Withdrew: Physician decision010
Withdrew: Lost to follow-up052

Outcome measures

PrimaryProgression Free Survival During Maintenance Phase

Progression free survival is defined as the time from randomization until the date of progression of disease (PD) or death from any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD is ≥20% increase in sum of longest diameter of target lesions. PD in maintenance phase uses the last lesion assessment prior to randomization as the baseline assessment.

Time frame:
Randomization to progression of disease (PD) or date of death from any cause up to 30.9 months
Reported as:
Median · months
Progression Free Survival During Maintenance Phase
monthsPemetrexed Plus Best Supportive Care (Maintenance Phase)Best Supportive Care (Maintenance Phase)
Progression Free Survival During Maintenance Phase3.2 (2.9 to 6.1)3.2 (2.2 to 4.3)
Statistical analysis
  • Pemetrexed Plus Best Supportive Care (Maintenance Phase) vs Best Supportive Care (Maintenance Phase) · Regression, Cox · p = 0.1815 (The significant level for the primary outcome measure of progression free survival during maintenance phase is one-sided 0.2.) · Hazard ratio (hr): 0.76 · 95% CI 0.42 to 1.37Stratified Cox regression model is used for hazard ratio estimate. Stratification factor: response status prior to randomization.
SecondaryProgression Free Survival During Overall Period (Induction Phase [IP] + Maintenance Phase [MP])

Progression-free survival in overall period is defined as the time from the date of first dose of study drug during IP until the date of PD or death from any cause. PD was determined using RECIST criteria. PD is ≥20% increase in sum of longest diameter of target lesions. PD in overall period uses the screening lesion assessment prior to the induction phase as the baseline assessment.

Time frame:
First dose of study drug during IP to PD or date of death from any cause up to 33.6 months
Reported as:
Median · months
Progression Free Survival During Overall Period (Induction Phase [IP] + Maintenance Phase [MP])
monthsPemetrexed Plus Best Supportive Care (Maintenance Phase)Best Supportive Care (Maintenance Phase)
Progression Free Survival During Overall Period (Induction Phase [IP] + Maintenance Phase [MP])6.2 (6.0 to 8.3)6.0 (4.6 to 6.9)
Statistical analysis
  • Pemetrexed Plus Best Supportive Care (Maintenance Phase) vs Best Supportive Care (Maintenance Phase) · Regression, Cox · p = 0.1233 (The significant level for the secondary outcome measure of progression free survival during overall period is one-sided 0.2.) · Hazard ratio (hr): 0.71 · 95% CI 0.40 to 1.26Stratified Cox regression model is used for hazard ratio estimate. Stratification factor: response status prior to randomization.
SecondaryOverall Survival During Maintenance Phase

Overall survival in maintenance phase is defined as the time from randomization to death. Participants who were alive were censored at the last contact.

Time frame:
Randomization to PD or date of death from any cause up to 31.3 months
Reported as:
Median · months
Overall Survival During Maintenance Phase
monthsPemetrexed Plus Best Supportive Care (Maintenance Phase)Best Supportive Care (Maintenance Phase)
Overall Survival During Maintenance Phase12.2 (5.6 to 20.6)11.8 (6.3 to 25.6)
Statistical analysis
  • Pemetrexed Plus Best Supportive Care (Maintenance Phase) vs Best Supportive Care (Maintenance Phase) · Regression, Cox · p = 0.7239 (The significant level for the secondary outcome measure overall survival during maintenance period is two-sided 0.05.) · Hazard ratio (hr): 1.13 · 95% CI 0.56 to 2.28Stratified Cox regression model is used for hazard ratio estimate. Stratification factor: response status prior to randomization.
SecondaryOverall Survival During Overall Period (IP + MP)

Overall survival in overall period is defined as the time from first dose of study drug during IP to death. Participants who were alive were censored at the last contact.

Time frame:
First dose of study drug during IP to PD or date of death from any cause up to 34.1 months
Reported as:
Median · months
Overall Survival During Overall Period (IP + MP)
monthsPemetrexed Plus Best Supportive Care (Maintenance Phase)Best Supportive Care (Maintenance Phase)
Overall Survival During Overall Period (IP + MP)15.4 (8.4 to 23.7)16.4 (9.1 to 28.5)
Statistical analysis
  • Pemetrexed Plus Best Supportive Care (Maintenance Phase) vs Best Supportive Care (Maintenance Phase) · Regression, Cox · p = 0.6376 (The significant level for the secondary outcome measure overall survival during overall period is two-sided 0.05.) · Hazard ratio (hr): 1.18 · 95% CI 0.59 to 2.38Stratified Cox regression model is used for hazard ratio estimate. Stratification factor: response status prior to randomization.
SecondaryNumber of Participants With Adverse Events (AEs) During Overall Period

The list of serious adverse events (SAEs) and other non-serious adverse events (AEs) are in Adverse Events Section.

Time frame:
First dose of study drug during IP through overall study completion (up to 34.3) months
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs) During Overall Period
participantsPemetrexed Plus Best Supportive Care (Maintenance Phase)Best Supportive Care (Maintenance Phase)Pemetrexed Plus Cisplatin (Induction Phase)
Adverse Events (AE)151674
Serious Adverse Events (SAE)1113
SecondaryTumor Response Rate and Disease Control Rate After Induction Phase (IP)

Tumor response rate (%) is the number of responders (participants with best response of CR or PR) divided by the number of participants qualified for tumor response according to RECIST criteria multiplied by 100. Disease control rate is percentage of participants with a best response of stable disease \[SD\], PR, or CR. CR=disappearance of all target lesions; PR=30% decrease in sum of longest diameter of target lesions; PD is≥20% increase in sum of longest diameter of target lesions. SD= neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Time frame:
Randomization to measured PD up to 31.4 months
Reported as:
Number · percentage of participants
Tumor Response Rate and Disease Control Rate After Induction Phase (IP)
percentage of participantsPemetrexed Plus Best Supportive Care (Maintenance Phase)Best Supportive Care (Maintenance Phase)
Best Overall Response Rate0 (0.0 to 12.3)0 (0.0 to 12.8)
CR0 (0 to 12.3)0 (0 to 12.8)
PR0 (0.0 to 12.3)0 (0.0 to 12.8)
SD57.1 (37.2 to 75.5)44.4 (25.5 to 64.7)
Disease Control Rate57.1 (37.2 to 75.5)44.4 (25.5 to 64.7)
PD32.1 (15.9 to 52.4)37.0 (19.4 to 57.6)
Early Death From Malignant Disease7.1 (0.9 to 23.5)0 (0.0 to 12.8)
Early Death From Toxicity0 (0.0 to 12.3)0 (0.0 to 12.8)
Early Death From other cause3.6 (0.1 to 18.3)0 (0.0 to 12.8)
Unknown0 (0.0 to 12.3)18.5 (6.3 to 38.1)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed Plus Best Supportive Care - Maintenance Phase—1/28 (3.6%)15/28 (53.6%)
Best Supportive Care - Maintenance Phase—1/27 (3.7%)16/27 (59.3%)
Pemetrexed + Cisplatin - Induction Phase—13/106 (12.3%)74/106 (69.8%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventPemetrexed Plus Best Supportive Care - Maintenance PhaseBest Supportive Care - Maintenance PhasePemetrexed + Cisplatin - Induction Phase
Sudden deathGeneral disorders0/281/272/106
Cardiac arrestCardiac disorders1/280/270/106
AnaemiaBlood and lymphatic system disorders0/280/271/106
Acute myocardial infarctionCardiac disorders0/280/271/106
DeafnessEar and labyrinth disorders0/280/271/106
DiarrhoeaGastrointestinal disorders0/280/271/106
VomitingGastrointestinal disorders0/280/271/106
DeathGeneral disorders0/280/271/106
Weight decreasedInvestigations0/280/271/106
Altered state of consciousnessNervous system disorders0/280/271/106
Most frequent other events
Showing 10 of 20
Most frequent other events
EventPemetrexed Plus Best Supportive Care - Maintenance PhaseBest Supportive Care - Maintenance PhasePemetrexed + Cisplatin - Induction Phase
VomitingGastrointestinal disorders2/280/2735/106
Decreased appetiteMetabolism and nutrition disorders2/283/2726/106
FatigueGeneral disorders3/284/2725/106
AnaemiaBlood and lymphatic system disorders5/283/2714/106
CoughRespiratory, thoracic and mediastinal disorders1/284/2710/106
DyspnoeaRespiratory, thoracic and mediastinal disorders3/284/279/106
Chest painGeneral disorders4/283/278/106
NauseaGastrointestinal disorders2/280/2715/106
NeutropeniaBlood and lymphatic system disorders3/281/2711/106
GastritisGastrointestinal disorders2/281/278/106

Baseline characteristics

Age Continuous
Age Continuous(years)Pemetrexed Plus Best Supportive Care (Maintenance Phase)Best Supportive Care (Maintenance Phase)Total
Mean57.4 ± 12.5262.9 ± 9.9760.1 ± 11.57
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed Plus Best Supportive Care (Maintenance Phase)Best Supportive Care (Maintenance Phase)Total
Female81018
Male201737
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pemetrexed Plus Best Supportive Care (Maintenance Phase)Best Supportive Care (Maintenance Phase)Total
Caucasian262652
African213
Region of Enrollment
Region of Enrollment(participants)Pemetrexed Plus Best Supportive Care (Maintenance Phase)Best Supportive Care (Maintenance Phase)Total
Egypt241943
Saudi Arabia011
Lebanon4711
Pathological Diagnosis
Pathological Diagnosis(participants)Pemetrexed Plus Best Supportive Care (Maintenance Phase)Best Supportive Care (Maintenance Phase)Total
Mixed Cell Carcinoma, Lung112
Large Cells Lung Carcinoma8513
Adenocarcinoma192140
Stage of Disease at The Time of Entry into This Study
Stage of Disease at The Time of Entry into This Study(participants)Pemetrexed Plus Best Supportive Care (Maintenance Phase)Best Supportive Care (Maintenance Phase)Total
Stage III B - Locally advanced91019
Stage IV - Metastasized191736
Eastern Cooperative Oncology Group (ECOG) Performance Status at randomization of maintenance phase
Eastern Cooperative Oncology Group (ECOG) Performance Status at randomization of maintenance phase(participants)Pemetrexed Plus Best Supportive Care (Maintenance Phase)Best Supportive Care (Maintenance Phase)Total
0 - Fully active6814
1 - Ambulatory, restricted strenuous activity201737
2 - Ambulatory, unable to carry out work activity224
Lesion Response to induction phase
Lesion Response to induction phase(participants)Pemetrexed Plus Best Supportive Care (Maintenance Phase)Best Supportive Care (Maintenance Phase)Total
Complete Response (CR)011
Partial Response (PR)101121
Stable Disease (SD)171330
Unknown123
08

Study locations

5 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Assiut, 0000, Egypt
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cairo, 11372, Egypt
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mounofia, 32514, Egypt
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beirut, Lebanon
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Riyadh, 11211, Saudi Arabia
09

References and documents

Publications

  • Mubarak N, Gaafar R, Shehata S, Hashem T, Abigeres D, Azim HA, El-Husseiny G, Al-Husaini H, Liu Z. A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer. BMC Cancer. 2012 Sep 24;12:423. doi: 10.1186/1471-2407-12-423. PubMed 23006447 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2011, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2008
First posted
Feb 1, 2008
Start
Jan 2008
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Results first posted
Dec 26, 2011
Last update
Dec 26, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00606021
Responsible party
Sponsor
First posted
Feb 1, 2008
Start date
Jan 2008
Primary completion
Dec 2010
Completion
Dec 2010
Results posted
Dec 26, 2011
Last update
Dec 26, 2011

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9am to 5pm Eastern Time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemetrexed

Start the discussion